AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

BACKGROUND: BRAF mutation is associated with poor clinical outcome of patients with malignant tumours, and mediates resistance to chemotherapy and targeted therapy. This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rui, Xu, Ling, Qu, Xiujuan, Che, Xiaofang, Zhang, Ye, Fan, Yibo, Li, Ce, Guo, Tianshu, Hou, Kezuo, Hu, Xuejun, Drew, Lisa, Shen, Minhui, Cheung, Tony, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988692/
https://www.ncbi.nlm.nih.gov/pubmed/29755114
http://dx.doi.org/10.1038/s41416-018-0086-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988692/
https://www.ncbi.nlm.nih.gov/pubmed/29755114
http://dx.doi.org/10.1038/s41416-018-0086-x

Ejemplares similares